Cardlytics (NASDAQ: CDLX) reported Q3 EPS of ($0.15), versus $0.20 reported last year. Revenue for the quarter came in at $34.6 million versus the consensus estimate of $37.58 million.

• Total revenue was $34.6 million, an increase of 10% year-over-year, compared to $31.4 million in the third quarter of 2017.
• Cardlytics Direct revenue was $34.4 million, an increase of 14%, compared to $30.2 million in the third quarter of 2017.
• GAAP net loss attributable to common stockholders was $(8.4) million, or $(0.40) per diluted share, based on 21.0 million weighted-average common shares outstanding, compared to a loss of $(2.8) million, or $(0.80) per diluted share, based on 3.5 million weighted-average common shares outstanding in the third quarter of 2017.
• Non-GAAP net loss was $(3.1) million, or $(0.15) per diluted share, based on 21.0 million non-GAAP weighted-average common shares outstanding, compared to a loss of $(2.8) million, or $(0.20) per diluted share, based on 14.2 million non-GAAP weighted-average common shares outstanding in the third quarter of 2017.
• Adjusted contribution, a non-GAAP metric, was $17.0 million compared to $17.2 million in the third quarter of 2017. During the third quarter of 2017, adjusted contribution included the impact of a non-cash gain totaling $3.0 million related to the reversal of an accrued expense for an expected shortfall in meeting a minimum FI Share commitment.
• Adjusted EBITDA, a non-GAAP metric, was a loss of $(1.7) million compared to a gain of $0.1 million in the third quarter of 2017. During the third quarter of 2017, adjusted EBITDA included the impact of a non-cash gain totaling $3.0 million related to the reversal of an accrued expense for an expected shortfall in meeting a minimum FI Share commitment.

For earnings history and earnings-related data on Cardlytics (CDLX) click here.